Fortress Biotech (NASDAQ:FBIO) Receives FDA Approval for UNLOXCYT™ for Treatment of cSCCOn December 13, 2024, Fortress Biotech, Inc. released an 8-K filing announcing a significant development for its majority-controlled subsidiary, Checkpoint Therap

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Fortress Biotech’s 8K filing here. About Fortress Biotech (Get Free Report) Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, […]

Leave a Reply

Your email address will not be published.

Previous post CareTrust REIT, Inc. (NASDAQ:CTRE) Plans $0.29 Quarterly Dividend
Next post Paramount Global (NASDAQ:PARA) Short Interest Update